title: Large-scale production and purification of VLP-based vaccines.
abstract: Virus-like particles (VLPs) hold tremendous potential as vaccine candidates. These innovative biopharmaceuticals present the remarkable advantages of closely mimicking the three-dimensional nature of an actual virus while lacking the virus genome packaged inside its capsid. As a result, an equally efficient but safer prophylaxis is anticipated as compared to inactivated or live attenuated viral vaccines. With the advent of successful cases of approved VLP-based vaccines, pharmaceutical companies are indeed redirecting their resources to the development of such products. This paper reviews the current choices and trends of large-scale production and purification of VLP-based vaccines generated through the baculovirus expression vector system using insect cells.
authors.affiliation: Animal Cell Technology Unit, IBET, Apartado 12, P-2781-901 Oeiras, Portugal.
authors.forename: Tiago
authors.initials: T
authors.lastname: Vicente
authors.forename: António
authors.initials: A
authors.lastname: Roldão
authors.forename: Cristina
authors.initials: C
authors.lastname: Peixoto
authors.forename: Manuel J T
authors.initials: MJ
authors.lastname: Carrondo
authors.forename: Paula M
authors.initials: PM
authors.lastname: Alves
mesh_terms: D000818:Animals; D016367:Baculoviridae / Q000235:genetics / Q000276:immunology; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D011786:Quality Control; D013678:Technology, Pharmaceutical; D058425:Vaccines, Virus-Like Particle / Q000276:immunology*; D014771:Virion / Q000276:immunology*
chemical_list: D058425:Vaccines, Virus-Like Particle